This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech, and Proviva Therapeutics securing US$30M for its PD-1/IL-2 prodrug. Clinical developments feature Pfizer’s zavegepant nasal spray filing in China, Rhegen’s Phase II mRNA shingles vaccine, and Innovent’s approval of picankibart for psoriasis. Other key updates include Transcenta’s positive data on osemitamab in G/GEJ cancer, Apeiron’s promising Phase I results for GTA182 in MTAP-deficient NSCLC, and DualityBio’s FDA IND clearance for ADC DB-1324.
